Global mycoplasma testing market to rise at 12.25% CAGR growth until 2027

It is expected to grow by $645.5m within the forecast period.

The global market for mycoplasma testing is projected to grow by $645.5m until 2027 at a compound annual growth rate (CAGR) of 12.25%.

A report by Technavio revealed that the market is driven by the rising prevalence of mycoplasma infections, the growing awareness of their health implications, and advancements in testing technologies. 

“Technologies like polymerase chain reaction (PCR) and microscopy are commonly used for Mycoplasma detection.” The report said.

Furthermore, the market is driven by the need for early and accurate diagnosis to reduce healthcare costs and prevent complications.

However, high costs associated with mycoplasma testing systems, assays, and consumables, along with PCR and viral culture limitations, serve as challenges that could impede market growth.

“For instance, PCR may not detect all Mycoplasma strains, while viral culture is time-consuming and requires specific conditions. Additionally, the lack of effective antimicrobial treatments for Mycoplasma infections adds to the challenges,” The report added.